Lichen sclerosus mimicking halo‐naevus comedonicus

T. Jouary(Hôpital Saint-André), Alain Taı̈eb(Université de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Khaled Ezzedine(Hôpitaux Universitaires Henri-Mondor), J.‐F. Goussot(Hôpital Cardiologique du Haut-Lévêque), S. Guillet(Assistance Publique – Hôpitaux de Paris), C. Droitcourt(Centre Hospitalier Universitaire de Rennes)
Journal of the European Academy of Dermatology and Venereology
October 29, 2014
10.1111/jdv.12800
Cited by 1

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k